Insulin aspart, recombinant Subcutaneous and Limbrel500
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Limbrel500 and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: bioflavonoids / zinc glycinate
Brand name: Limbrel250, Limbrel500
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Limencin
- Insulin aspart, recombinant Subcutaneous-Linaclotide
- Insulin aspart, recombinant Subcutaneous-Linagliptin
- Insulin aspart, recombinant Subcutaneous-Linagliptin and metformin
- Insulin aspart, recombinant Subcutaneous-Linagliptin and Metformin Extended-Release Tablets
- Insulin aspart, recombinant Subcutaneous-Linagliptin and Metformin Tablets
- Limbrel500-Insulin degludec
- Limbrel500-Insulin Degludec (U-100) Prefilled Pens
- Limbrel500-Insulin Degludec (U-100) Vials
- Limbrel500-Insulin Degludec (U-200) Prefilled Pens
- Limbrel500-Insulin degludec and liraglutide
- Limbrel500-Insulin degludec and liraglutide Subcutaneous